Dr. Nabil Adra, MD
Claim this profileIndiana University Melvin and Bren Simon Cancer Center
Studies Prostate Cancer
Studies Cancer
15 reported clinical trials
32 drugs studied
Affiliated Hospitals
Clinical Trials Nabil Adra, MD is currently running
ARX517 + Enzalutamide
for Prostate Cancer
This trial is testing ARX517, a new drug, in adults with advanced prostate cancer that doesn't respond to usual treatments. The study aims to see if the drug is safe and effective in stopping or slowing down cancer growth.
Recruiting1 award Phase 17 criteria
Immunotherapy + Chemotherapy
for Bladder Cancer
Upon successful screening and registration, enrollment to durvalumab monotherapy (cohort 1) will begin. If DLT criteria outlined in the protocol are exceeded with durvalumab monotherapy (cohort 1), the study will close. Provided the safety of durvalumab monotherapy is established, enrollment to combination regimen cohorts will proceed. Cohorts will simultaneously enroll in parallel to each other with patients assigned to cohorts based on patient slot availability and study site choice of radiation arm participation. Patient assignment to future phase 1 arms would proceed similarly. Within BCG-containing cohorts, treatment will begin at full-dose BCG. If DLT criteria outlined in Section 5.1.4 are exceeded with full-dose BCG, a one level dose reduction of BCG will be implemented. If DLT criteria outlined in Section 5.1.4 are exceeded with reduced-dose BCG, the BCG-containing cohort will not proceed to Phase 2 of the study. Similarly, if DLT criteria outlined in Section 5.1.4 are exceeded within non-BCG containing cohorts, the non-BCG containing cohort will not proceed to phase 2 of the study. Due to the prolonged half-life of antibody therapies, no dose adjustments are planned for durvalumab in any of the cohorts.
Recruiting1 award Phase 1 & 26 criteria
More about Nabil Adra, MD
Clinical Trial Related4 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Nabil Adra, MD has experience with
- Nivolumab
- Cabozantinib
- Docetaxel
- ARX517
- 177Lu-J591
- Ketoconazole
Breakdown of trials Nabil Adra, MD has run
Prostate Cancer
Cancer
Tumors
Germ Cell Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Nabil Adra, MD specialize in?
Nabil Adra, MD focuses on Prostate Cancer and Cancer. In particular, much of their work with Prostate Cancer has involved Stage IV patients, or patients who are undergoing treatment.
Is Nabil Adra, MD currently recruiting for clinical trials?
Yes, Nabil Adra, MD is currently recruiting for 7 clinical trials in Indianapolis Indiana. If you're interested in participating, you should apply.
Are there any treatments that Nabil Adra, MD has studied deeply?
Yes, Nabil Adra, MD has studied treatments such as Nivolumab, Cabozantinib, Docetaxel.
What is the best way to schedule an appointment with Nabil Adra, MD?
Apply for one of the trials that Nabil Adra, MD is conducting.
What is the office address of Nabil Adra, MD?
The office of Nabil Adra, MD is located at: Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202 United States. This is the address for their practice at the Indiana University Melvin and Bren Simon Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.